Immunome (NASDAQ:IMNM) Issues Earnings Results, Beats Expectations By $0.12 EPS

12 May 2026, 16:26 by Scott Moore · The Cerbat Gem

Immunome (NASDAQ:IMNM – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12, FiscalAI reports.

Immunome Trading Down 1.3%

NASDAQ IMNM traded down $0.31 during trading hours on Tuesday, reaching $22.69. 1,235,758 shares of the company traded hands, compared to its average volume of 1,372,706. Immunome has a 12 month low of $7.42 and a 12 month high of $27.65. The stock has a market capitalization of $2.57 billion, a PE ratio of -9.38 and a beta of 2.11. The company has a 50 day moving average of $21.97 and a two-hundred day moving average of $21.05.

Insider Buying and Selling at Immunome

In other Immunome news, CFO Max Rosett sold 65,000 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the transaction, the chief financial officer directly owned 54,037 shares in the company, valued at $1,184,491.04. This represents a 54.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $20.47, for a total transaction of $753,296.00. Following the completion of the transaction, the director owned 369,347 shares in the company, valued at approximately $7,560,533.09. The trade was a 9.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 139,438 shares of company stock worth $2,964,664 in the last ninety days. 7.21% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Aster Capital Management DIFC Ltd acquired a new position in Immunome during the 4th quarter valued at about $121,000. BNP Paribas Financial Markets increased its stake in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares during the period. Russell Investments Group Ltd. acquired a new position in Immunome during the 3rd quarter valued at about $76,000. Tower Research Capital LLC TRC increased its stake in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after buying an additional 3,802 shares during the period. Finally, Ensign Peak Advisors Inc acquired a new position in Immunome during the 4th quarter valued at about $165,000. 44.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Stephens lowered their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Craig Hallum raised their price target on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Immunome in a report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.45.

Get Our Latest Analysis on Immunome

Immunome Company Profile

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.